Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atezolizumab companion diagnostic - Foundation Medicine

Next Previous
Drug Profile

Atezolizumab companion diagnostic - Foundation Medicine

Alternative Names: Atezolizumab bTMB assay

Latest Information Update: 28 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Foundation Medicine
  • Developer Foundation Medicine; Roche
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Non-small cell lung cancer

Most Recent Events

  • 28 Sep 2022 Atezolizumab companion diagnostic is still in phase-II/III clinical trials for Non-small cell lung cancer (Diagnosis) in Japan, Israel, Turkey, Thailand, Singapore, Taiwan, Serbia, Peru, Russia, Peru, New Zealand, New Zealand, Panama, Netherlands, Mexico, Hong Kong, Germany, France, Brazil, Costa Rica, Belgium, Argentina (PO)(NCT03178552)
  • 28 Sep 2020 Phase II/III clinical trials are ongoing in Non-small cell lung cancer (Diagnosis) in Japan, Israel, Turkey, Thailand, Singapore, Taiwan, Serbia, Peru, Russia, Peru, New Zealand, New Zealand, Panama, Netherlands, Mexico, Hong Kong, Germany, France, Brazil, Costa Rica, Belgium, Argentina, USA, Australia, Canada, Chile, Italy, South Korea, Poland, Spain (unspecified route) (NCT03178552)
  • 22 Sep 2017 Phase-II/III clinical trials in Non-small cell lung cancer (Diagnosis) in USA, Australia, Canada, Chile, Italy, South Korea, Poland, Spain (PO) (NCT03178552)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top